To examine the association between statin out‐of‐pocket () costs and utilization among the Medicare Part D population.
2006–2008 administrative claims and enrollment data for the 5 percent Medicare sample.
Sample included 346,583 beneficiary‐year observations of statin users enrolled in stand‐alone prescription drug plans, excluding low‐income subsidy recipients. We estimated the association between a plan's statin costs and statin utilization using an instrumental variable approach to account for potential bias due to plan selection. Adherence was defined as percentage of days covered () of at least 80 percent. Plan costs were constructed for a representative market basket of statin medications. Analyses controlled for demographic characteristics, cardiovascular disease risk, co‐morbidity presence, and regional characteristics.
About 67 percent of the sample had a of at least 80 percent. An increase in annual statin from $200 (50th percentile) to $240 (75th percentile) was associated with a reduction in the rate of adherent beneficiaries from 67 percent to 56 percent ( < .001).
Greater costs for statins are associated with reductions in statin utilization.
Data Sources/Study Setting